Implementation of first-trimester screening and prevention of preeclampsia

Implementation of first-trimester screening and prevention of preeclampsia: a stepped wedge cluster-randomized trial in Asia FORECAST - FORECAST

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190035

Enrollment

7800

Registered

2019-05-30

Start date

2019-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk pregnancy for preterm-preeclampsia identified by screening at 11-13 weeks preeclampsia

Interventions

Low-dose aspirin is prescribed every night from before 15 weeks to 36 weeks of gestation to prevent PE in a woman who is at the age of 18 and older, who was screened for PE in an intervention period,

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Singleton pregnancy

Exclusion criteria

Exclusion criteria: Multiple pregnancy, Major fetal defects identified at 11-13 weeks of assessment, Non-viable fetus

Design outcomes

Primary

Measure	Time frame
Delivery with preeclampsia at < 37 weeks of gestation	—

Secondary

Measure	Time frame
Abnormal pregnancy outcome (preeclampsia, gestational hypertension, low birth weight infant (SGA; less than 5th percentile of birth weight), stillbirth, placental abruption) at less than 34 weeks of gestation, 34 to 37 weeks of gestation, 37 weeks of gestation or later	—

Countries

China, Hong Kong, Japan, Philippines, Singapore, Taiwan, Thailand, Vietnam

Contacts

Public ContactArihiro Shiozaki

Toyama University Hospital

s33shio@med.u-toyama.ac.jp+81-76-434-7357

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026